Trial Profile
Open-label, Multicenter Phase 1 Study of Mogamulizumab (KW-0761) in Combination With Docetaxel in Previously Treated Subjects With Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Mogamulizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin; Kyowa Kirin Pharmaceutical Development
- 05 Jan 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.